Good morning :)
Place Order
Add to Watchlist

Aarti Pharmalabs Ltd

AARTIPHARM

Aarti Pharmalabs Ltd

AARTIPHARM
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹5,235 cr, stock is ranked 724
High RiskStock is 3.52x as volatile as Nifty
577.757.82% (-49.00)
577.757.82% (-49.00)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹5,235 cr, stock is ranked 724
High RiskStock is 3.52x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹5,235 cr, stock is ranked 724
High RiskStock is 3.52x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
24.142.980.52%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
44.495.960.56%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.

Investor Presentation

View older 

Sep 14, 2023

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue0.000.001,202.451,947.551,857.511,857.50
Raw Materialssubtract0.000.00686.721,295.121,040.671,466.56
Power & Fuel Costsubtract0.0044.1475.1084.03
Employee Costsubtract0.0085.20121.32128.03
Selling & Administrative Expensessubtract0.0227.35110.2897.65
Operating & Other expensessubtract0.00149.581.37116.19
Depreciation/Amortizationsubtract0.000.0042.1262.5473.2473.23
Interest & Other Itemssubtract0.000.0011.9621.0517.2117.22
Taxes & Other Itemssubtract0.000.0033.1367.2883.5983.59
EPS-0.800.004,890.0042.5823.9323.93
DPS0.000.000.002.003.002.00
Payout ratio0.000.000.050.130.08

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2023

Annual report

PDF

Investor Presentation

Jun 26PDF
FY 2024

Annual report

PDF

Investor Presentation

Sep 14PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareLabs & Life Sciences Services

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aarti Pharmalabs Ltd24.142.980.52%
Divi's Laboratories Ltd74.998.840.66%
Syngene International Ltd59.027.070.17%
Dishman Carbogen Amcis Ltd-16.510.44

Price Comparison

Compare AARTIPHARM with any stock or ETF
Compare AARTIPHARM with any stock or ETF
AARTIPHARM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.26%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding46.46%4.69%6.78%7.06%35.01%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun7.69%7.43%8.45%8.16%8.32%7.06%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.97%

Top 5 Mutual Funds holding Aarti Pharmalabs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Quant Small Cap Fund - Growth - Direct Plan

Growth
1.1308%0.28%0.28%111/119 (+1)
Aditya Birla Sun Life Flexi Cap Fund - Growth - Direct Plan

Growth
0.9421%0.24%0.05%80/91 (-6)
Quant Flexi Cap Fund - Growth - Direct Plan

Growth
0.7155%0.65%0.65%65/71 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

Cash Dividend

Ex DateEx DateJul 31, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Jul 31, 2024

Past Dividends

Cash Dividend

Ex DateEx DateFeb 16, 2024

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

2.00

Ex DateEx Date

Feb 16, 2024